Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Chembio Diagnostics, Inc (NASDAQ: CEMI).

Full DD Report for CEMI

You must become a subscriber to view this report.


Recent News from (NASDAQ: CEMI)

Chembio Diagnostics, Inc. (CEMI) CEO John Sperzel on Q2 Results - Earnings Call Transcript
Chembio Diagnostics, Inc. (CEMI) Q2 2018 Earnings Conference Call August 08, 2018 04:30 p.m. ET Executives John Sperzel - President, Chief Executive Officer Neil Goldman - Chief Financial Officer Analysts Per Ostlund - Craig-Hallum Capital Group Ross Taylor - ARS Investment...
Source: SeekingAlpha
Date: August, 12 2018 21:51
Chembio Diagnostics misses by $0.05, beats on revenue
Chembio Diagnostics (NASDAQ: CEMI ): Q2 EPS of -$0.12 misses by $0.05 . More news on: Chembio Diagnostics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 08 2018 16:38
Chembio Diagnostics Appoints Dr. Mary Lake Polan to its Board of Directors
MEDFORD, N.Y., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care ("POC") diagnostic testing, today announced that Mary Lake Polan, M.D., Ph.D., M.P.H., has been appointed to its Board of Directors.  Dr. Mary Lake Polan is...
Source: GlobeNewswire
Date: August, 08 2018 16:06
Chembio Diagnostics Reports Second Quarter 2018 Financial Results
MEDFORD, N.Y., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care diagnostic testing, today reported financial results for the second quarter ended June 30, 2018. Recent Accomplishments & Highlights Achieved total revenue of $8.7...
Source: GlobeNewswire
Date: August, 08 2018 16:01
Your Daily Pharma Scoop: Redhill Zooms, FDA Nods Advaxis Ahead, Hologic Warned
Stocks in News: RDHL, ADXS RedHill's RHB-104 successful in late-stage Crohn's study; shares up 40% premarket Discussion : RedHill Biopharma’s ( RDHL ) RB-104 succeeds in Phase 3 clinical trial on Crohn's disease patients. Primary endpoint of remission at 26th week against the d...
Source: SeekingAlpha
Date: July, 31 2018 08:29
Chembio Diagnostics collaborates with FIND to develop HCV point-of-care diagnostic test
Chembio Diagnostics (NASDAQ: CEMI ) collaborates with the Foundation for Innovative New Diagnostics (FIND) to expedite the feasibility testing of a rapid diagnostic test for hepatitis C virus (HCV). More news on: Chembio Diagnostics, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: July, 30 2018 06:00
Chembio Diagnostics Announces Collaboration with FIND to Develop Hepatitis C Virus Point-of-Care Diagnostic Test
MEDFORD, N.Y. and GENEVA, July 28, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic testing, today announced a collaboration with the Foundation for Innovative New Diagnostics (FIND) to expedite the feasibility testing of a rapid...
Source: GlobeNewswire
Date: July, 28 2018 08:00
Chembio Diagnostics to Participate in the Canaccord Genuity Growth Conference
MEDFORD, N.Y., July 26, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic testing, today announced the Company plans to participate in the upcoming Canaccord Genuity Growth Conference in Boston, MA. Chembio’s management ...
Source: GlobeNewswire
Date: July, 26 2018 16:05
Chembio Diagnostics to Report Second Quarter 2018 Financial Results on August 8, 2018
MEDFORD, N.Y., July 25, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic testing, announced today that it will release financial results for the second quarter 2018 after the close of trading on Wednesday, August 8, 2018.  T...
Source: GlobeNewswire
Date: July, 25 2018 16:05
Chembio Diagnostics Appoints Christine Rousseau, Ph.D. as Vice President, Corporate Development
MEDFORD, N.Y., July 19, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic testing, today announced the appointment of Christine M. Rousseau, Ph.D. as Vice President, Corporate Development, effective immediately. In this newly crea...
Source: GlobeNewswire
Date: July, 19 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0810.1010.2010.2010.090210,201
2018-08-0111.3511.5011.5011.3531,007
2018-07-3111.3011.3511.3511.2521,430
2018-07-3011.4011.3011.4011.2535,156
2018-07-2711.1511.2511.2611.155,639

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1816,02420,12479.6263Short
2018-12-172,48013,02819.0359Cover
2018-12-147,40013,38155.3023Short
2018-12-139,91614,81366.9412Short
2018-12-123,05022,73213.4172Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CEMI.


About Chembio Diagnostics, Inc (NASDAQ: CEMI)

Logo for Chembio Diagnostics, Inc (NASDAQ: CEMI)

Not available

 

Contact Information

 

 

Current Management

  • Lawrence A. Siebert / President, CEO
  • Richard J. Larkin / CFO
  • Susan Norcott / IR
  • Katherine L. Davis /
  • Barbara DeBuono /
  • Peter Kissinger /
  • Gary Meller /
  • Lawrence A. Siebert /

Current Share Structure

  • Market Cap: $123,923,643 - 05/15/2018
  • Issue and Outstanding: 14,162,702 - 03/05/2018

 


Recent Filings from (NASDAQ: CEMI)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018

 

 


Daily Technical Chart for (NASDAQ: CEMI)

Daily Technical Chart for (NASDAQ: CEMI)


Stay tuned for daily updates and more on (NASDAQ: CEMI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CEMI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CEMI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CEMI and does not buy, sell, or trade any shares of CEMI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/